RNS Number : 3061G Renalytix PLC 23 July 2021 Renalytix plc (" Renalytix " or the " Company ") Director/PDMR Dealing New York , 23 July 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling , the Company's Chief Financial Officer, of 12,000
Hutson to Build on Renalytix Quality and Regulatory Strategy for KidneyIntelX Global Commercialization NEW YORK and SALT LAKE CITY, July 22, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Joseph Hutson as its Vice President of Quality and
RNS Number : 0685G Renalytix PLC 22 July 2021 Renalytix plc (" Renalytix " or the " Company ") Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory Hutson To Build-on Renalytix Quality and Regulatory Strategy for KidneyIntelX Global Commercialization NEW YORK
RNS Number : 7167F Renalytix PLC 19 July 2021 Renalytix plc (" Renalytix " or the " Company ") Exercise of Options and TVR NEW YORK , 19 July, 2021 - Renalytix plc (AIM: RENX) announces that it has issued and allotted 5,000 ordinary shares of 0.25 pence each in the share capital of the
RNS Number : 3722E Renalytix PLC 07 July 2021 Renalytix plc (" Renalytix " or the " Company ") Exercise of options, PDMR transaction and TVR NEW YORK , 7 July, 2021 - The Board of Renalytix plc (LSE: RENX) announces that it has issued and allotted 27,500 ordinary shares of 0.25 pence
RNS Number : 9118D Renalytix PLC 01 July 2021 Renalytix plc (" Renalytix " or the " Company ") Death of Director NEW YORK , 1 July, 2021 - The Board of Renalytix plc (LSE: RENX) (NASDAQ: RNLX) is saddened to announce the death of Dr. Barbara Murphy , Non-Executive Director and
RNS Number : 7147D Renalytix PLC 01 July 2021 Renalytix plc (" Renalytix " or the " Company ") Total voting rights The Company's total issued share capital consists of 72,197,286 shares of 0.25 pence each, with each share carrying the right to one vote.
Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and pharma collaborations NEW YORK, June 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces new data demonstrating KidneyIntelX™ can be effective at monitoring therapeutic response and
RNS Number : 3397D Renalytix PLC 28 June 2021 Renalytix plc ("Renalytix" or the "Company") Director/PDMR Dealing The Company had been informed today that Christopher Mills , a non-executive director and interim Chairman, completed the sale of 6,100 ordinary shares of 0.25 pence each
RNS Number : 2844D Renalytix PLC 28 June 2021 Renalytix plc (" Renalytix " or the " Company ") KidneyIntelX TM Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time Study Results lay foundation for KidneyIntelX repeat testing, reimbursement, and
